Skip to main content
SpringerLink
Log in

Targeting CD30/CD30L in Oncology and Autoimmune and Inflammatory Diseases

  • Chapter
Therapeutic Targets of the TNF Superfamily

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 647))

Abstract

The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin’s disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin’s lymphomas (NHLs). Increased CD30L expression was found on mast cells within HD tumors and preclinical and clinical studies with compounds targeting the CD30/ CD30L system in HD and ALCL demonstrated therapeutic benefit. Upregulation of CD30 and CD30L is also linked to leukocytes in patients with chronic inflammatory diseases, including lupus erythematosus, asthma, rheumatoid arthritis and atopic dermatitis (AD). Preclinical studies conducted with transgenic mice or biologic compounds suggested important regulatory functions of the CD30-CD30L system in various aspects of the immune system. Such key regulatory roles and their low expression in normal conditions combined with increased expression in malignant tissues provided a strong rationale to investigate CD30 and CD30L as therapeutic targets in hematologic malignancies, autoimmune and inflammatory diseases. In this report, we review the pharmacodynamic effects of specific therapeutic compounds targeting the CD30/CD30L system in preclinical- and clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Smith CA et al. CD30 antigen, a marker for Hodgkin’s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993; 73(7):1349–60.

    Article  PubMed  CAS  Google Scholar 

  2. Gruss H J, Duyster J, Herrmann. Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin’s disease. Ann Oncol 1996; 7 Suppl 4:19–26.

    PubMed  Google Scholar 

  3. Durkop H et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell 1992; 68(3):421–7.

    Article  PubMed  CAS  Google Scholar 

  4. Cabanillas F et al. Lymphomatoid papulosis: a T-cell dyscrasia with a propensity to transform into malignant lymphoma. Ann Intern Med 1995; 122(3):210–7.

    PubMed  CAS  Google Scholar 

  5. Berro AI, Perry GA, Agrawal DK. Increased expression and activation of CD30 induce apoptosis in human blood eosinophils. J Immunol 2004; 173(3):2174–83.

    PubMed  CAS  Google Scholar 

  6. Agrawal B, Reddish M, Longenecker BM. CD30 expression on human CD8+ T-cells isolated from peripheral blood lymphocytes of normal donors. J Immunol 1996; 157(8):3229–34.

    PubMed  CAS  Google Scholar 

  7. Romagnani S et al. Role for CD30 in HIV expression. Immunol Lett 1996; 51(1–2):83–8.

    Article  PubMed  CAS  Google Scholar 

  8. Durkop H et al. Expression of the CD30 antigen in nonlymphoid tissues and cells. J Pathol 2000; 190(5):613–8.

    Article  PubMed  CAS  Google Scholar 

  9. Kaudewitz P et al. Atypical cells in lymphomatoid papulosis express the Hodgkin cell-associated antigen Ki-1. J Invest Dermatol 1986; 86(4):350–4.

    Article  PubMed  CAS  Google Scholar 

  10. Chiarle R et al. CD30 in normal and neoplastic cells. Clin Immunol 1999; 90(2):157–64.

    Article  PubMed  CAS  Google Scholar 

  11. Granados S, Hwang ST. Roles for CD30 in the biology and treatment of CD30 lymphoproliferative diseases. J Invest Dermatol 2004; 122(6):345–7.

    Article  CAS  Google Scholar 

  12. Stein H et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic and clinical features. Blood 2000; 96(12):3681–95.

    PubMed  CAS  Google Scholar 

  13. Younes A, ME Kadin. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003; 21(18):3526–34.

    Article  PubMed  CAS  Google Scholar 

  14. Zinzani PL et al. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J Clin Oncol 1996; 14(3):955–62.

    PubMed  CAS  Google Scholar 

  15. Pizzolo G, Romagnani S. CD30 molecule (Ki-1 Ag): more than just a marker of CD30+ lymphoma. Haematologica 1995; 80(4):357–66.

    PubMed  CAS  Google Scholar 

  16. Iyn H et al. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. J Rheumatol 2000; 27(3):698–702.

    Google Scholar 

  17. McMillan SA et al. Evaluation of the clinical utility of cerebrospinal fluid (CSF) indices of inflammatory markers in multiple sclerosis. Acta Neurol Scand 2000; 101(4):239–43.

    Article  PubMed  CAS  Google Scholar 

  18. Horn-Lohrens O et al. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer 1995; 60(4):539–44.

    Article  PubMed  CAS  Google Scholar 

  19. Nadali G et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin’s disease at high risk of unfavorable outcome. Blood 1998; 91(8):3011–6.

    PubMed  CAS  Google Scholar 

  20. Pizzolo G et al. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin’s disease: relationship with disease activity and clinical stage. Br J Haematol 1990; 75(2):282–4.

    Article  PubMed  CAS  Google Scholar 

  21. Pizzolo G et al. High serum level of soluble CD30 in acute primary HIV-1 infection. Clin Exp Immunol 1997; 108(2):251–3.

    Article  PubMed  CAS  Google Scholar 

  22. Caligaris-Cappio F et al. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol 1995; 13(3):339–43.

    PubMed  CAS  Google Scholar 

  23. Gerli R et al. High levels of the soluble form of CD30 mole cule in rheumatoid arthritis (RA) are expression of CD30+ T-cell involvement in the inflamed joints. Clin Exp Immunol 1995; 102(3):547–50.

    Article  PubMed  CAS  Google Scholar 

  24. Okumura M et al. Increased serum concentration of soluble CD30 in patients with Graves’ disease and Hashimoto’s thyroiditis. J Clin Endocrinol Metab 1997; 82(6):1757–60.

    Article  PubMed  CAS  Google Scholar 

  25. Bengtsson A et al. Elevated serum levels of soluble CD30 in patients with atopic dermatitis (AD). Clin Exp Immunol 1997; 109(3):533–7.

    Article  PubMed  CAS  Google Scholar 

  26. Dummer W, Brocker EB, Bastian BC. Elevated serum levels of soluble CD30 are associated with atopic dermatitis, but not with respiratory atopic disorders and allergic contact dermatitis. Br J Dermatol 1997; 137(2):185–7.

    Article  PubMed  CAS  Google Scholar 

  27. Caproni M et al. In vivo relevance of CD30 in atopic dermatitis. Allergy 1997; 52(11):1063–70.

    Article  PubMed  CAS  Google Scholar 

  28. Frezzolini A et al. Soluble CD30 in pediatric patients with atopic dermatitis. Allergy 1997; 52(1):106–9.

    Article  PubMed  CAS  Google Scholar 

  29. Heshmat NM, El-Hadidi ES. Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age. Pediatr Allergy Immunol 2006; 17(4):297–303.

    Article  PubMed  Google Scholar 

  30. Leonard C et al. Allergen-induced CD30 expression on T-cells of atopic asthmatics. Clin Exp Allergy 1997; 27(7):780–6.

    Article  PubMed  CAS  Google Scholar 

  31. Nogueira JM et al. Soluble CD30, dehydroepiandrosterone sulfate and dehydroepiandrosterone in atopic and non-atopic children. Allerg Immunol (Paris) 1998; 30(1):3–8.

    CAS  Google Scholar 

  32. Croager EJ, Abraham LJ. Characterisation of the human CD30 ligand gene structure. Biochim Biophys Acta 1997; 1353(3):231–5.

    PubMed  CAS  Google Scholar 

  33. Gattei V et al. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 1997; 89(6):2048–59.

    PubMed  CAS  Google Scholar 

  34. Gruss HJ et al. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994; 83(8):2045–56.

    PubMed  CAS  Google Scholar 

  35. Gruss HJ et al. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines. Leukemia 1994; 8(12):2083–94.

    PubMed  CAS  Google Scholar 

  36. Nicod LP, Isler P. Alveolar macrophages in sarcoidosis coexpress high levels of CD86 (B7.2), CD40 and CD30L. Am J Respir Cell Mol Biol 1997; 17(1):91–6.

    PubMed  CAS  Google Scholar 

  37. Pinto A et al. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin’s disease cell line. Blood 1996; 88(9):3299–305.

    PubMed  CAS  Google Scholar 

  38. Shanebeck KD et al. Regulation of murine B-cell growth and differentiation by CD30 ligand. Eur J Immunol 1995; 25(8):2147–53.

    Article  PubMed  CAS  Google Scholar 

  39. Wiley SR, Goodwin RG, Smith CA. Reverse signaling via CD30 ligand. J Immunol 1996; 157(8):3635–9.

    PubMed  CAS  Google Scholar 

  40. Younes A et al. CD30 ligand is expressed on resting normal and malignant human B-lymphocytes. Br J Haematol 1996; 93(3):569–71.

    Article  PubMed  CAS  Google Scholar 

  41. Molin D et al. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin’s disease. Br J Haematol 2001; 114(3):616–23.

    Article  PubMed  CAS  Google Scholar 

  42. Duckett CS, Thompson CB. CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev 1997; 11(21):2810–21.

    Article  PubMed  CAS  Google Scholar 

  43. Aizawa S et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem 1997; 272(4):2042–5.

    Article  PubMed  CAS  Google Scholar 

  44. Duckett CS et al. Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol 1997; 17(3):1535–42.

    PubMed  CAS  Google Scholar 

  45. Horie R et al. A novel domain in the CD30 cytoplasmic tail mediates NFkappaB activation. Int Immunol 1998; 10(2):203–10.

    Article  PubMed  CAS  Google Scholar 

  46. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 2000; 96(13):4307–12.

    PubMed  CAS  Google Scholar 

  47. Boll B et al. The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis. Blood 2005; 106(5):1839–42.

    Article  PubMed  CAS  Google Scholar 

  48. Chiarle R et al. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol 1999; 163(1):194–205.

    PubMed  CAS  Google Scholar 

  49. Gilfillan MC et al. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunol 1998; 160(5):2180–7.

    PubMed  CAS  Google Scholar 

  50. Podack ER et al. CD30-governor of memory T-cells? Ann N Y Acad Sci 2002; 975:101–13.

    Article  PubMed  CAS  Google Scholar 

  51. Gaspal FM et al. Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T-cell memory. J Immunol 2005; 174(7):3891–6.

    PubMed  CAS  Google Scholar 

  52. Fischer M et al. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest 2006; 116(10):2748–56.

    Article  PubMed  CAS  Google Scholar 

  53. Schneider C, Hubinger G. Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family. Leuk Lymphoma 2002; 43(7):1355–66.

    Article  PubMed  CAS  Google Scholar 

  54. Hsu PL, Hsu SM. Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: distinction between Hodgkin’s disease and anaplastic large cell lymphoma. Lab Invest 2000; 80(7):1111–9.

    PubMed  CAS  Google Scholar 

  55. Tian ZG et al. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res 1995; 55(22):5335–41.

    PubMed  CAS  Google Scholar 

  56. Pfeifer W et al. A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1). Am J Pathol 1999; 155(4):1353–9.

    PubMed  CAS  Google Scholar 

  57. Wahl AF et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin’s disease. Cancer Res 2002; 62(13):3736–42.

    PubMed  CAS  Google Scholar 

  58. Cerveny, CG et al. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin’s disease cells to conventional chemotherapeutics. Leukemia 2005; 19(9):1648–55.

    Article  PubMed  CAS  Google Scholar 

  59. Klimka A et al. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA’) is a potent immunotoxin against a Hodgkin-derived cell line. Br J Cancer 1999; 80(8):1214–22.

    Article  PubMed  CAS  Google Scholar 

  60. Pasqualucci L et al. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. Blood 1995; 85(8):2139–46.

    PubMed  CAS  Google Scholar 

  61. Falini B et al. Response of refractory Hodgkin’s disease to monoclonal anti-CD30 immunotoxin. Lancet 1992; 339(8803):1195–6.

    Article  PubMed  CAS  Google Scholar 

  62. Hamblett KJ et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004; 10(20):7063–70.

    Article  PubMed  CAS  Google Scholar 

  63. Francisco JA et al. AC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003; 102(4):1458–65.

    Article  PubMed  CAS  Google Scholar 

  64. Falini B et al. In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin’s disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence. Br J Haematol 1992; 82(1):38–45.

    Article  PubMed  CAS  Google Scholar 

  65. Schnell R et al. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin’s lymphoma. Ann Oncol 2003; 14(5):729–36.

    Article  PubMed  CAS  Google Scholar 

  66. Hartmann F et al. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin’s disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res 2001; 7(7):1873–81.

    PubMed  CAS  Google Scholar 

  67. Hartmann F et al. Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody. Blood 1997; 89(6):2042–7.

    PubMed  CAS  Google Scholar 

  68. Borchmann P et al. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood 2002; 100(9):3101–7.

    Article  PubMed  CAS  Google Scholar 

  69. Schnell R et al. Treatment of refractory Hodgkin’s lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 2005; 23(21):4669–78.

    Article  PubMed  CAS  Google Scholar 

  70. Hartmann F et al. Treatment of Hodgkin’s disease with bispecific antibodies. Ann Oncol 1996; 7Suppl 4:143–6.

    PubMed  Google Scholar 

  71. Bartlett NL et al. Phase I study of SGN-30, a chimeric monoclonal antibody (mAB) in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2002; 100(11):Abs 1403.

    Google Scholar 

  72. Carabasi M et al. Pharmacokinetics, safety and tolerability of SGN-30, a chimeric monoclonal antibody (mAb), administered as a single dose to patients with CD30+ hematologic malignancies. Proc Am Soc Clin Oncol 2003; 22:Abs 722.

    Google Scholar 

  73. Bartlett NL et al. Safety, antitumor activity and pharmacokinetics of six weekly doses of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2003; 102(11):Abs 2390.

    Google Scholar 

  74. Leonard J et al. Phase II study to SGN-30 (Anti-CD30 monoclonal antibody) in patients with refractory or recurrent Hodgkin’s disease. Blood 2004; 104(11):Abs 2635.

    Google Scholar 

  75. Forero A et al. Initial phase II results of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL). J Proc Am Soc Clin Oncol 2005; 24: Abs 6601.

    Google Scholar 

  76. Schnell R, Borchmann P. SGN-30 (Seattle genetics). Curr Opin Mol Ther 2006; 8(2):164–72.

    PubMed  CAS  Google Scholar 

  77. Shimozato O et al. Expression of CD30 ligand (CD153) on murine activated T-cells. Biochem Biophys Res Commun 1999; 256(3):519–26.

    Article  PubMed  CAS  Google Scholar 

  78. Chakrabarty S et al. Critical roles of CD30/CD30L interactions in murine autoimmune diabetes. Clin Exp Immunol 2003; 133(3):318–25.

    Article  PubMed  CAS  Google Scholar 

  79. Beckmann J et al. The role of CD30 in skin and heart allograft rejection in the mouse. Transplant Proc 2001; 33(1–2):140–1.

    Article  PubMed  CAS  Google Scholar 

  80. Florido M et al. Contribution of CD30/CD153 but not of CD27/CD70, CD134/OX40L, or CD137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium. J Leukoc Biol 2004; 76(5):1039–46.

    Article  PubMed  CAS  Google Scholar 

  81. Blazar BR et al. CD30/CD30 ligand (CD153) interaction regulates CD4+ T-cell-mediated graft-versus-host disease J Immunol 2004; 173(5):2933–41.

    PubMed  CAS  Google Scholar 

  82. Zeiser R et al. Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T-cells in prevention of acute graft versus host disease. Blood 2006.

    Google Scholar 

  83. Polte T, Behrendt AK, Hansen G. Direct evidence for a critical role of CD30 in the development of allergic asthma. J Allergy Clin Immunol 2006; 118(4):942–8.

    Article  PubMed  CAS  Google Scholar 

  84. Lane PJ et al. CD4+CD3− cells regulate the organization of lymphoid tissue and T-cell memory for antibody responses. Int J Hematol 2006; 83(1):12–6.

    Article  PubMed  CAS  Google Scholar 

  85. Kennedy MK, Willis CR, Armitage RJ. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 2006; 118(2):143–52.

    Article  PubMed  CAS  Google Scholar 

  86. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003; 361(9352):151–60.

    Article  PubMed  Google Scholar 

  87. Simpson EL, Hanifin JM. Atopic dermatitis. Med Clin North Am 2006; 90(1):149–67, ix.

    Article  PubMed  Google Scholar 

  88. Folster-Holst R et al. Soluble CD30 plasma concentrations correlate with disease activity in patients with atopic dermatitis. Acta Derm Venereol, 2002; 82(4):245–8.

    Article  PubMed  Google Scholar 

  89. Caproni M et al. Soluble CD30 and cyclosporine in severe atopic dermatitis. Int Arch Allergy Immunol 2000; 121(4):324–8.

    Article  PubMed  CAS  Google Scholar 

  90. Bottari V et al. Cyclosporin A (CyA) reduces sCD30 serum levels in atopic dermatitis: a possible new immune intervention. Allergy 1999; 54(5):507–10.

    Article  PubMed  CAS  Google Scholar 

  91. Gerli R et al. Role of CD30+ T-cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol 2001; 22(2):72–7.

    Article  PubMed  CAS  Google Scholar 

  92. Okamoto A et al. Pathophysiological functions of CD30+CD4+ T-cells in rheumatoid arthritis. Acta Med Okayama 2003; 57(6):267–77.

    PubMed  CAS  Google Scholar 

  93. Ciferska H et al. The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value. Clin Rheumatol 2006.

    Google Scholar 

  94. Gerli R et al. CD30+ T-cells in rheumatoid synovitis: mechanisms of recruitment and functional role. J Immunol 200; 164(8):4399–407.

    Google Scholar 

  95. Oflazoglu E et al. CD30 expression on CD10a+ and CD8+ cells in atopic dermatitis and correlation with disease severity. Eur J Dermatol. 2008; 18:41–49.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Preclinical Therapeutics, Seattle Genetics, Inc, 21823 30th Drive, Southeast, Bothell, Washington, 9802, USA

    Ezogelin Oflazoglu, Iqbal S. Grewal & Hanspeter Gerber

Authors
  1. Ezogelin Oflazoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Iqbal S. Grewal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hanspeter Gerber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Preclinical Therapeutics, Seattle Genetics, Inc., Bothell, Washington, USA

    Iqbal S. Grewal PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Landes Bioscience and Springer Science+Business Media

About this chapter

Cite this chapter

Oflazoglu, E., Grewal, I.S., Gerber, H. (2009). Targeting CD30/CD30L in Oncology and Autoimmune and Inflammatory Diseases. In: Grewal, I.S. (eds) Therapeutic Targets of the TNF Superfamily. Advances in Experimental Medicine and Biology, vol 647. Springer, New York, NY. https://doi.org/10.1007/978-0-387-89520-8_12

Download citation

Publish with us

Policies and ethics

Search

Navigation